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Palmar Bullous Blistering Induced by Erlotinib
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A 56-year-old female was allocated to definite radiotherapy of66 Gy (5 weekly fractions of 2 Gy) because of stage III
non-small cell lung cancer (T1bN3M0, middle-differentiated
adenocarcinoma). Epidermal growth factor receptor (EGFR)
mutation test was negative. Standard concomitant platinum-
based chemotherapy was avoided because of a chronic kidney
disease. As an alternative, concomitant erlotinib 150 mg once a
day was prescribed based on the possible radiosensitizing effect
by targeting the EGFR, even in the absence of EGFR mutation.1
After a few days, she developed mild acneiform facial rash and
mild diarrhea. Twenty-three days after the start of the treatment,
she noticed a small blister in one of her palms. A severe skin
reaction developed rapidly within the next 2 days and included
painful hemorrhagic palmar bullae (Figure 1), maculopapular
erythema with desquamating elements on the trunk and extrem-
ities, and generalized pruritus. Erlotinib was stopped after 25
days of treatment. Aspiration of bullous fluid and biopsies from
the palm on day 27 was evaluated to be consistent with a bullous
drug reaction (Figure 2). The skin reaction improved gradually
during symptomatic treatment with topic hydrocortisone, an
antihistamine, antibiotics, and 1 week of prednisolone 20 mg
once a day.
The US Food and Drug Administration warns against
bullous, blistering, and exfoliative skin disorders induced by
erlotinib (www.fda.gov). Oteri et al.2 recently reported a case
of localized bullous dermatitis limited to one of the upper
extremities. With the increasing use of erlotinib and other
EGFR-targeting agents, early recognition of uncommon but
potentially severe skin reactions should be emphasized.
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FIGURE 1. Acute onset of palmar bullous dermatitis 23
days after the start of erlotinib. Picture taken on day 25, 2
days after the first appearance. Photo courtesy: Per Marius
Didriksen, Oslo University Hospital.
FIGURE 2. Histological biopsy showing intraepidermal bul-
lae of varying size (squares), spongiosis (long red arrow),
subepithelial edema (short red arrow), and a dermal leuko-
cytic infiltrate composed of lymphocytes and plasma cells
(long black arrow), and eosinophils (short black arrow), con-
sistent with a bullous drug reaction. Photo courtesy: Marius
Lund-Iversen, Oslo University Hospital.
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